CFS_for_19_years
Hoarder of biscuits
- Messages
- 2,396
- Location
- USA
http://www.hemispherx.net/content/investor/default.asp?goto=833
.Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe
Philadelphia, PA, Monday, August 10, 2015: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the “Company” or “Hemispherx”), reported today that it has executed an agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.
myTomorrows, as Hemispherx’ exclusive service provider in Europe and Turkey, will perform EAP activities in Europe and Turkey to include the supply of rintatolimod for the treatment of Chronic Fatigue Syndrome (CFS) to patients with an unmet medical need.
Govert Shouten, Ph.D, Co-Founder & CBO at myTomorrows, said “Rintatolimod for CFS fits perfectly with the raison d'être of myTomorrows. CFS affects as many people in Europe as in the US and there is no drug approved anywhere specifically for CFS. In clinical trials rintatolimod has shown promising results for certain CFS patients particularly those most severely affected.
As we do with other life-threatening and debilitating diseases such as cancer, MS, and depression, myTomorrows will set up and roll out the early access programs needed to help these patients